

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



October 29, 2025

Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)

Company name:	Japan Lifeline Co., Ltd.	
Listing:	Tokyo Stock Exchange	
Securities code:	7575	
URL:	https://www.japanlifeline.com/	
Representative:	Keisuke Suzuki, President and CEO	
Inquiries:	Takeyoshi Egawa, Director and Chief Financial Officer	
Telephone:	+81-3-6711-5200	
Scheduled date to file semi-annual securities report:	November 14, 2025	
Scheduled date to commence dividend payments:	—	
Preparation of supplementary material on financial results:	Yes	
Holding of financial results briefing:	Yes (for institutional investors and analysts)	

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2025 (April 1, 2025–September 30, 2025)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent	
Six months ended September 30, 2025	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
September 30, 2024	29,285	4.6	6,620	5.7	6,624	7.4	4,774	7.7
	27,985	11.4	6,260	14.4	6,167	9.7	4,435	10.0

Note: Comprehensive income Six months ended September 30, 2025: ¥4,667 million [(0.3)%]
Six months ended September 30, 2024: ¥4,680 million [11.8%]

	Basic earnings per share	Diluted earnings per share
Six months ended September 30, 2025	Yen	Yen
September 30, 2024	68.08	68.08
	61.87	—

(2) Consolidated financial position

	Total assets	Total net assets	Equity ratio
As of September 30, 2025	Millions of yen	Millions of yen	%
March 31, 2025	75,274	60,977	81.0
	75,123	59,914	79.8

Reference: Equity (Shareholders' equity + Accumulated other comprehensive income)

As of September 30, 2025: ¥60,965 million

As of March 31, 2025: ¥59,914 million

2. Dividends

	Annual dividends per share				
	Q1-end	Q2-end	Q3-end	Year-end	Total
Fiscal year ended March 31, 2025	Yen —	Yen 0.00	Yen —	Yen 53.00	Yen 53.00
Fiscal year ending March 31, 2026	—	0.00	—	—	—
Fiscal year ending March 31, 2026 (forecast)	—	—	—	54.00	54.00

Note: Revisions to the most recently announced dividends forecast: None

3. Consolidated earnings forecast for the fiscal year ending March 31, 2026 (April 1, 2025–March 31, 2026)
 (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Net income attributable to owners of the parent		Basic earnings per share
Full year	Millions of yen 59,300	% 4.8	Millions of yen 12,900	% 4.7	Millions of yen 13,000	% 5.4	Millions of yen 9,350	% 0.3	Yen 133.30

Note: Revisions to the most recently announced earnings forecast: None

*** Notes**

(1) Changes in significant subsidiaries (changes in specified subsidiaries resulting in changes in the scope of consolidation) during the period: None

(2) Application of accounting treatments specific to the preparation of semi-annual consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

- (i) Changes in accounting policies due to revisions to accounting standards and other pronouncements: None
- (ii) Changes in accounting policies due to reasons other than (i): None
- (iii) Changes in accounting estimates: None
- (iv) Restatement: None

(4) Number of shares issued (common stock)

(i) Total number of shares issued at the end of the period (including treasury stock)

As of September 30, 2025	71,300,000 shares
As of March 31, 2025	75,758,470 shares

(ii) Number of shares of treasury stock at the end of the period

As of September 30, 2025	1,143,752 shares
As of March 31, 2025	5,661,667 shares

(iii) Average number of shares outstanding during the period

Six months ended September 30, 2025	70,129,451 shares
Six months ended September 30, 2024	71,683,209 shares

Note: The Company has adopted a Board Incentive Plan (BIP) trust, assuming the Company's shares held by the trust are shares of treasury stock in "(4) Number of shares issued (common stock)."

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecast, and other special matters

The forward-looking statements including earnings forecasts contained in this document are based on information currently available to the Company and certain assumptions that are deemed to be reasonable. Accordingly, the Company does not guarantee the achievement of the forecast, and actual results may differ significantly from the forecast due to various factors. For the assumptions for earnings forecasts and cautions concerning the use thereof, please refer to "1. Overview of Financial Performance, (3) Consolidated financial guidance" on page 6 of the attached materials.

Contents of Attached Materials

1. Overview of Financial Performance	2
(1) Operating results	2
(2) Financial position	6
(3) Consolidated financial guidance	6
2. Interim Consolidated Financial Statements and Major Notes	8
(1) Interim consolidated balance sheets	8
(2) Interim consolidated statements of income and interim consolidated statements of comprehensive income	9
(3) Interim consolidated statements of cash flows	10
(4) Notes to interim consolidated financial statements	11
<i>Going concern assumption</i>	11
<i>Significant changes in shareholders' equity</i>	11
<i>Interim consolidated statements of cash flows</i>	11
<i>Segment information, etc.</i>	11
3. Other	12
Status of production, orders received and sales	12

1. Overview of Financial Performance

(1) Operating results

Forward-looking statements below are based on our judgment as of September 30, 2025.

Business environment

Japan Lifeline operates in the medical device sector, primarily focusing on cardiac devices for general hospitals in Japan. As Japan's population ages, the demand for medical care is rising, a trend expected to persist. However, the medical care supply is under strain, raising concerns about the sustainability of various medical services. To address this, the government is promoting working-style reform for doctors to reduce the chronic long working hours faced by medical professionals.

In this competitive environment, it's crucial for us not only to offer effective medical devices but also to help solve broader healthcare sustainability issues. We have been tackling these challenges by leveraging its dual role as both manufacturer and distributor to build a flexible and robust product portfolio.

Status of business

For the six months ended September 30, 2025, we saw year-over-year increases across key financial metrics. Net sales increased by 4.6%, gross profit rose by 3.5%, operating profit grew by 5.7%, and net income attributable to owners of the parent increased by 7.7%. The business environment has been undergoing substantial changes, including the revision of reimbursement prices in June 2024 and the rapid adoption of Pulsed Field Ablation ("PFA"), a new treatment for atrial fibrillation advanced by our competitors. Amid this situation, we steadily promoted continuously introducing competitive products and expanding new therapeutic areas, key initiatives in the medium-term management plan (from the fiscal year ended March 31, 2024 to the fiscal year ending March 31, 2028). As a result, business performance progressed largely in line with the initial guidance.

Our core businesses EP/Ablation and Cardiovascular performed well, with sales up 4.1% and 5.0% year-over-year, respectively, driven by the growth in core products. Specifically, in EP/Ablation, sales of intracardiac defibrillation catheters were strong against the backdrop of an increase in atrial fibrillation ablation procedures. In addition, hemostatic devices for femoral vein experienced a smooth progress in expanding facility adoption. In Cardiovascular, the Frozen Elephant Trunk (FET) remained solid due to market expansion.

The sales volume of new therapeutic areas within high-growth businesses increased driven by a broader product lineup, with Neurovascular sales up 48.4% and Gastrointestinal up 15.7%*1 year-over-year.

Cardiac Rhythm Management, positioned as a stable business, posted a 0.9% year-over-year decrease in sales, mainly reflecting a decline in the company's market share due to weaker pacemaker sales.

Selling, general and administrative expenses increased by 234 million yen year-over-year due to factors including higher personnel and research and development expenses, partially offset by reversal of allowance for doubtful accounts due to the partial collection of bad debts. Nevertheless, the higher sales volume absorbed the impact of the increased expenses. As a result, operating profit for the period under review increased 359 million yen, with the operating margin of 22.6%.

We recognize that volatility in foreign currency exchange rates had a limited impact on our business performance. This is because our third-party product purchases made in yen accounted for approximately 75% of all transactions. Additionally, we use the moving-average method for cost of sales, which smooths out the impact of any temporary increases in procurement costs over time.

*1 Sales of Gastrointestinal included those from the terminated coronary intervention business; without this business, sales would have increased 25.0% year-over-year.

Business Performance

The earnings for the six months ended September 30, 2025 were as follows:

(Millions of yen, unless otherwise noted)

Product Category	Six months ended September 30, 2024		Six months ended September 30, 2025		YoY increase/ (decrease)	YoY % increase/ (decrease)
	Amount	% of net sales	Amount	% of net sales		
(i) Net sales	27,985	100.0	29,285	100.0	1,299	4.6
(ii) Gross profit	16,963	60.6	17,557	60.0	593	3.5
(iii) Operating profit	6,260	22.4	6,620	22.6	359	5.7
(iv) Ordinary profit	6,167	22.0	6,624	22.6	456	7.4
(v) Net income attributable to owners of the parent	4,435	15.8	4,774	16.3	339	7.7

(i) Net sales

Net sales were 29,285 million yen, an increase of 4.6% year-over-year. For more details, please refer to the “Sales by product” section later in this report.

(ii) Gross profit

Gross profit was 17,557 million yen, up 3.5% year-over-year. While the decline in sales prices—stemming from the revisions to the reimbursement prices in June 2024—affected results for two months compared to the same period of the previous fiscal year, increased sales volume in the core and high-growth businesses offset the impact.

The gross margin reached 60.0%, a decrease of 60 bps year-over-year due to the decline in sales prices noted above and the deterioration in the product mix. Note that proprietary sales mix fell to 55.1%, a decrease of 250 bps year-over-year.

(iii) Operating profit

We reported operating profit of 6,620 million yen, an increase of 5.7% year-over-year, and operating margin of 22.6% (an increase of 20 bps year-over-year). Selling, general and administrative expenses increased by 234 million yen year-over-year. The main reasons for increase/decrease are as follows:

(Reasons for increase)

- Higher personnel expenses from salary increases
- An increase in research and development expenses related to the development of PFA systems and other projects
- An increase in sales-related expenses due to higher business activity

(Reason for decrease)

- Recognition of reversal of allowance for doubtful accounts due to the partial collection of bad debts (provision of allowance for doubtful accounts from suspended customer transactions was recorded in the previous fiscal year)

(iv) Ordinary profit

Ordinary profit was 6,624 million yen, up 7.4% year-over-year. Non-operating income totaled 95 million yen, including interest income and dividend income. Non-operating expenses of 90 million yen included foreign exchange losses and loss on valuation of investment securities.

(v) Net income attributable to owners of the parent

Net income attributable to owners of the parent was 4,774 million yen, marking a 7.7% increase year-over-year. The income tax burden was 27.5%, down 70 bps.

Sales by product

(Millions of yen, unless otherwise noted)

Product Category	Six months ended September 30, 2024	Six months ended September 30, 2025	YoY increase/ (decrease)	YoY % increase/ (decrease)
Cardiac Rhythm Management	6,725	6,666	(59)	(0.9)
EP/Ablation	14,123	14,707	583	4.1
Cardiovascular	5,656	5,936	280	5.0
Neurovascular	800	1,187	387	48.4
Gastrointestinal	680	787	107	15.7
Total	27,985	29,285	1,299	4.6

*Note: The main products classified in each product category are as follows.

Cardiac Rhythm Management

Pacemaker, T-ICD (Transvascular Implantable Cardioverter Defibrillator), S-ICD (Subcutaneous Implantable Cardioverter Defibrillator), CRT-P (Cardiac Resynchronization Therapy Pacemaker), CRT-D (Cardiac Resynchronization Therapy Defibrillator), AED (Automated External Defibrillator), lead management device

EP/Ablation

Electrophysiology catheter, ablation catheter, endoscopic laser ablation catheter, intracardiac defibrillation catheter, esophageal temperature monitoring catheter, steerable sheath, hemostatic device for femoral vein

Cardiovascular

Vascular graft, Frozen Elephant Trunk, stent graft, atrial septum defect closure device

Neurovascular

Embolic coil, aspiration catheter, microcatheter, stent retriever

Gastrointestinal

Bile-duct tube stent, biliary dilation balloon, contrast catheter, double-lumen dilator, cholangioscope system, ERCP guide wire, colonic stent, gastro duodenal stent, RF needle for liver cancer treatment

(i) Cardiac Rhythm Management

Net sales in Cardiac Rhythm Management reached 6,666 million yen, a decrease of 0.9% year-over-year. Pacemaker sales were sluggish as leadless competitors gained market share. On the other hand, although slightly affected by competitors' new products, net sales of the core product S-ICD remained strong, supported by steady growth in sales volume. Additionally, the launch of the lead management device of Philips in May 2025 also contributed to this result.

(ii) EP/Ablation

Net sales in EP/Ablation reached 14,707 million yen, an increase of 4.1% year-over-year, marking a record high for the six-month period. Sales volume of the core product intracardiac defibrillation catheter increased, driven by an estimated 10% year-over-year rise in atrial fibrillation ablation procedures. In addition, expansion into new markets for hemostatic devices for femoral vein progressed steadily. On the other hand, some EP catheters, such as esophageal temperature monitoring catheters, saw sluggish sales due to the market penetration of PFA, a new treatment for atrial fibrillation advanced by our competitors.

(iii) Cardiovascular

Net sales in Cardiovascular reached 5,936 million yen, an increase of 5.0% year-over-year. The core product Frozen Elephant Trunk performed well with the high market share maintained, as a result of focusing on targeted sales initiatives, including procedure training programs utilizing the product. The following factors also contributed to the result: (1) the launch of pressure-sensor-equipped guide wire for Transcatheter Aortic Valve Implantation (TAVI) as a new product in the Structural Heart Disease area in the second quarter of the current fiscal year, and (2) the supply of the cell delivery catheter system in regenerative medicine products for Heartseed Inc.

(iv) Neurovascular

Net sales in Neurovascular reached 1,187 million yen, an increase of 48.4% year-over-year. Sales of aspiration catheters were significantly driven by a newly introduced peripheral vascular model. Stent retrievers, fully released in the third quarter of the previous fiscal year, started off stably. Embolic coil sales remained robust, driven by our expanded reach through the introduction of an interventional radiology model.

(v) Gastrointestinal

Net sales in Gastrointestinal amounted to 787 million yen, an increase of 15.7% year-over-year. Excluding the coronary intervention business, which was terminated in the fiscal year ended March 31, 2024, adjusted net sales increased 25.0% to 747 million yen. Sales of the bile-duct tube stent were higher than expected on the back of favorable clinical evaluations of the new model introduced in the first quarter of the current fiscal year. Sales of other products, including ERCP guide wires and biliary dilation balloons, were also solid.

(2) Financial position

Analysis of the interim consolidated balance sheets

(i) Assets

The balance of current assets as of September 30, 2025 was 44,824 million yen, an increase of 488 million yen from the end of the previous fiscal year. This was mainly due to increases of 604 million yen in notes and accounts receivable – trade and 1,184 million yen in inventories, partially offset by a decrease of 1,384 million yen in cash and deposits, resulting from payments for dividends and income taxes.

The balance of fixed assets was 30,450 million yen, a decrease of 336 million yen from the end of the previous fiscal year. This was mainly due to decreases of 276 million yen in long-term prepaid expenses and 219 million yen in deferred tax assets included in “Other” under investments and other assets, partially offset by an increase of 288 million yen in leasehold and guarantee deposits in “Other” under investments and other assets.

As a result, the balance of total assets was 75,274 million yen, an increase of 151 million yen from the end of the previous fiscal year.

(ii) Liabilities

The balance of current liabilities as of September 30, 2025 was 13,577 million yen, a decrease of 756 million yen from the end of the previous fiscal year. This was primarily due to decreases of 208 million yen in provisions for bonuses and 180 million yen in accrued expenses included in “Other.”

The balance of long-term liabilities was 719 million yen, a decrease of 154 million yen from the end of the previous fiscal year. This was mainly due to decreases of 85 million yen in provision for director’s stock based compensation and 34 million yen in long-term accounts payable – other included in “Other.”

As a result, the balance of total liabilities was 14,297 million yen, a decrease of 911 million yen from the end of the previous fiscal year.

(iii) Net assets

The balance of net assets as of September 30, 2025 was 60,977 million yen, an increase of 1,063 million yen from the end of the previous fiscal year. This was mainly due to dividend payments of 3,722 million yen, partially offset by the recording of net income attributable to owners of the parent of 4,774 million yen.

Analysis of the interim consolidated statements of cash flows

The balance of cash and cash equivalents as of September 30, 2025 amounted to 9,630 million yen, a decrease of 1,384 million yen from the end of the previous fiscal year. Cash flows for the first six months of the fiscal year ending March 31, 2026 by activities were as follows.

(i) Cash flow from operating activities

Net cash provided by operating activities was 3,495 million yen (for the first six months of the previous fiscal year, net cash provided by operating activities was 2,938 million yen). The main factors are profit before income taxes of 6,582 million yen, despite an increase in trade notes and accounts receivable of 606 million yen, an increase in inventories of 1,187 million yen, and income taxes paid of 1,543 million yen, which decreased cash flows.

(ii) Cash flows from investing activities

Net cash used in investing activities was 1,023 million yen (for the first six months of the previous fiscal year, net cash used in investing activities was 424 million yen), mainly due to purchase of property, plant and equipment of 672 million yen.

(iii) Cash flows from financing activities

Net cash used in financing activities was 3,880 million yen (for the first six months of the previous fiscal year, net cash used in financing activities was 7,187 million yen), mainly due to dividends paid of 3,718 million yen.

(3) Consolidated financial guidance

Our performance for the six months ended September 30, 2025 progressed steadily, almost in line with initial guidance. In Cardiac Rhythm Management and Gastrointestinal, performance showed slightly slower progress than initially expected, but this was offset by strong performance in Neurovascular and Cardiovascular. In EP/Ablation, the market penetration of PFA

resulted in a more severe decline in sales of some products than expected. However, overall performance remained strong as sales of core products including intracardiac defibrillation catheters and hemostatic devices for femoral vein exceeded expectations.

We anticipate sales will continue steadily into the second half and beyond. Expenditure is also expected to remain broadly aligned with planned allocations. Therefore, as of today, the full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, as announced on May 7, 2025, remains unchanged. Should any revisions become necessary, we will promptly disclose them.

2. Interim Consolidated Financial Statements and Major Notes

(1) Interim consolidated balance sheets

	(Millions of yen)	
	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and deposits	11,014	9,630
Notes and accounts receivable - trade	13,830	14,435
Inventories	17,961	19,146
Other	1,529	1,612
Total current assets	44,336	44,824
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	6,995	6,771
Other, net	6,289	6,373
Total property, plant and equipment	13,285	13,145
Intangible assets		
Investments and other assets		
Investment securities	7,374	7,563
Long-term loans receivable	2,691	2,682
Retirement benefit asset	405	377
Other	6,871	6,501
Allowance for doubtful accounts	(1,753)	(1,544)
Total investments and other assets	15,590	15,581
Total fixed assets	30,786	30,450
Total assets	75,123	75,274
Liabilities		
Current liabilities		
Notes and accounts payable - trade	4,358	4,455
Short-term borrowings	3,500	3,500
Current portion of long-term borrowings	120	60
Accounts payable - other	947	840
Income taxes payable	1,703	1,768
Provision for bonuses	1,946	1,738
Provision for bonuses for directors	79	21
Other	1,678	1,193
Total current liabilities	14,334	13,577
Long-term liabilities		
Provision for director's stock based compensation	164	78
Other	709	640
Total long-term liabilities	874	719
Total liabilities	15,208	14,297
Net assets		
Shareholders' equity		
Share capital	2,115	2,115
Capital surplus	8,888	4,418
Retained earnings	53,455	54,507
Treasury stock	(5,784)	(1,208)
Total shareholders' equity	58,675	59,833
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(32)	84
Foreign currency translation adjustment	788	666
Remeasurements of defined benefit plans	483	380
Total accumulated other comprehensive income	1,239	1,131
Share acquisition rights	–	12
Total net assets	59,914	60,977
Total liabilities and net assets	75,123	75,274

(2) Interim consolidated statements of income and interim consolidated statements of comprehensive income
 (Interim consolidated statements of income)

(Millions of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Net sales	27,985	29,285
Cost of sales	11,022	11,727
Gross profit	16,963	17,557
Selling, general and administrative expenses	10,703	10,937
Operating profit	6,260	6,620
Non-operating income		
Interest income	37	59
Dividend income	34	28
Reversal of allowance for doubtful accounts	5	–
Other	12	8
Total non-operating income	89	95
Non-operating expenses		
Interest expenses	18	18
Loss on valuation of investment securities	10	19
Foreign exchange losses	50	25
Provision of allowance for doubtful accounts	–	3
Commission expenses	64	7
Other	36	16
Total non-operating expenses	181	90
Ordinary profit	6,167	6,624
Extraordinary income		
Gain on sale of fixed assets	7	0
Gain on sale of investment securities	20	–
Total extraordinary income	27	0
Extraordinary losses		
Loss on sale of fixed assets	1	–
Loss on retirement of fixed assets	14	42
Total extraordinary losses	15	42
Profit before income taxes	6,179	6,582
Income taxes - current	1,571	1,608
Income taxes - deferred	173	199
Total income taxes	1,744	1,807
Net income	4,435	4,774
Net income attributable to owners of the parent	4,435	4,774

(Interim consolidated statements of comprehensive income)

(Millions of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Net income	4,435	4,774
Other comprehensive income		
Net unrealized holding gains or losses on securities	(56)	116
Foreign currency translation adjustment	319	(121)
Retirement benefits liability adjustment	(17)	(102)
Total other comprehensive income	245	(107)
Comprehensive income	4,680	4,667
Comprehensive income attributable to:		
Owners of the parent	4,680	4,667

(3) Interim consolidated statements of cash flows

(Millions of yen)

	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash flows from operating activities		
Profit before income taxes	6,179	6,582
Depreciation	861	814
Amortization of long-term prepaid expenses	159	159
Increase (decrease) in allowance for doubtful accounts	211	(208)
Increase (decrease) in provision for bonuses	(90)	(208)
Increase (decrease) in provision for bonuses for directors	(21)	(58)
Increase (decrease) in retirement benefit liability	(59)	(112)
Increase (decrease) in provision for directors' stock based compensation	(25)	(85)
Interest and dividend income	(71)	(87)
Interest expenses	18	18
Loss (gain) on sale and retirement of non-current assets	8	42
Loss (gain) on valuation of investment securities	10	19
Loss (gain) on sale of investment securities	(20)	—
Decrease (increase) in trade receivables	(584)	(606)
Decrease (increase) in inventories	(1,684)	(1,187)
Decrease (increase) in accounts receivable - other	18	(63)
Increase (decrease) in trade payables	(563)	97
Increase (decrease) in accrued consumption taxes	331	(104)
Increase (decrease) in accrued expenses	(150)	(180)
Other, net	(49)	188
Subtotal	4,476	5,019
Interest and dividends received	45	37
Interest paid	(18)	(18)
Income taxes paid	(1,564)	(1,543)
Net cash provided by (used in) operating activities	2,938	3,495
Cash flows from investing activities		
Purchase of property, plant and equipment	(802)	(672)
Purchase of intangible assets	(27)	(26)
Proceeds from sale of fixed assets	15	0
Purchase of investment securities	(637)	(40)
Proceeds from sale of investment securities	1,023	—
Long-term loan advances	(4)	(3)
Proceeds from collection of long-term loans receivable	7	5
Other payments	(1)	(407)
Other proceeds	2	119
Net cash provided by (used in) investing activities	(424)	(1,023)
Cash flows from financing activities		
Increase (decrease) in short-term borrowings	1,500	—
Repayments of long-term borrowings	(234)	(60)
Purchase of treasury stock	(5,225)	—
Repayments of lease liabilities	(74)	(101)
Dividends paid	(3,154)	(3,718)
Net cash provided by (used in) financing activities	(7,187)	(3,880)
Effect of exchange rate change on cash and cash equivalents	52	24
Net increase (decrease) in cash and cash equivalents	(4,621)	(1,384)
Cash and cash equivalents at beginning of period	12,669	11,014
Cash and cash equivalents at end of period	*¹ 8,047	*¹ 9,630

(4) Notes to interim consolidated financial statements

Going concern assumption

None

Significant changes in shareholders' equity

Cancellation of treasury stock

The Company canceled 4,458,470 shares of its treasury stock on May 16, 2025, pursuant to the resolution passed at the Board of Directors meeting held on May 7, 2025. As a result, during the six months ended September 30, 2025, capital surplus and treasury stock both decreased by 4,469 million yen.

As of September 30, 2025, capital surplus stood at 4,418 million yen, and treasury stock totaled 1,208 million yen.

Interim consolidated statements of cash flows

*1 The relationship between the balance of cash and cash equivalents at the end of the periods and the amount of items listed in the consolidated balance sheets is as follows:

	(Millions of yen)	
	Six months ended September 30, 2024	Six months ended September 30, 2025
Cash and deposits	8,047	9,630
Cash and cash equivalents	8,047	9,630

Segment information, etc.

[Segment information]

Six months ended September 30, 2024 (from April 1, 2024 to September 30, 2024)

The Company and its consolidated subsidiaries are engaged in the manufacture and sale of medical devices, with principal customers located in Japan. There are no reportable segments among the components of the Company and its consolidated subsidiaries for which discrete financial information is available and whose operating results are regularly reviewed by the Board of Directors to make decisions about management resources to be allocated and assess business performance.

Six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

The Company and its consolidated subsidiaries are engaged in the manufacture and sale of medical devices, with principal customers located in Japan. There are no reportable segments among the components of the Company and its consolidated subsidiaries for which discrete financial information is available and whose operating results are regularly reviewed by the Board of Directors to make decisions about management resources to be allocated and assess business performance.

3. Other

Status of production, orders received and sales

(i) Production

The production results for the six months ended September 30, 2024 and 2025, by product category, were as follows. There were no significant changes.

Product Category	Six months ended September 30, 2024	Six months ended September 30, 2025	(Millions of yen) YoY % increase/ (decrease)
Cardiac Rhythm Management	10	5	(50.3)
EP/Ablation	3,176	3,132	(1.4)
Cardiovascular	769	836	8.7
Gastrointestinal	366	384	4.9
Total	4,323	4,358	0.8

Notes: 1. Figures are based on manufacturing cost.

2. Since there was no production in the “Neurovascular” category in either the previous or current fiscal year, it has been omitted.

(ii) Orders received

As the Group’s business model generally does not generate order backlogs, this information is omitted.

(iii) Sales results

Please refer to “1. Overview of Financial Performance (1) Operating results” on page 2 of the attached materials.